Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-004 Pilot Study in HIV-Infected Adults on HAART
NCT00381212Phase 2Completed
- Sponsor
- McGill University Health Centre
- Start
- Sep 2006
- Primary completion
- Feb 2008
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rocapuldencel-T in human immunodeficiency virus type 1 infection (HIV-1), sponsored by McGill University Health Centre. Primary endpoint: Immunologic activity of AGS-004 at 18 weeks. Started Sep 2006; status: completed.
02
Drugs
rocapuldencel-T
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00381212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381212.